Latest From AgaMatrix Inc.
Amazon's recent partnership with the Arcadia Group to supply blood glucose strips and meters under the new brand name Choice is another move by the retail giant to disrupt the health-care sector using the path of least resistance.
Innovative technology from companies such as Google offers the promise of new digital health options in the glucose monitoring market, while drastic reimbursement cuts affecting existing meters and supplies in the US are taking a noticeable toll on the major players already operating in the field. These competing factors have created a dichotomy characterized by opportunity on one side and uncertainly on the other, and that is forcing some competitors to re-think their business strategies.
Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.
With the removal of a near-term competitive threat to Sanofi’s hallmark insulin franchise, 2013 is poised to be a momentum-building year for the big pharma, and more specifically, its diabetes business. The opportunity can’t come too soon, as the company launches the GLP-1 agonist Lyxumia into a crowded and fiercely competitive field.
In Vitro Diagnostics
- Glucose Testing
- Monitoring Equipment & Devices
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- AgaMatrix Inc.
- Senior Management
John Alberico, CEO
George Doherty, CFO
David Conn, Chief Commercial Officer
Ian Harding, PhD, Dir., Applied Rsch.
- Contact Info
Phone: (603) 328-6000
10 Manor Pkwy.
Salem, NH 03079
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.